Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development

Current Medicinal Chemistry

Volumn 18, Issue 5, 2011, Pages 667-713

  He, S M ^a   Zhou, Z W ^b   Li, X T ^c   Zhou, S F ^d  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b RMIT UNIVERSITY   (Australia)

^c FUDAN UNIVERSITY   (China)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Clearance; CYP2C9; Drug development; Polymorphism; Toxicity

Indexed keywords

ACECLOFENAC; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ALPRAZOLAM; AMIODARONE; AMITRIPTYLINE; AMPRENAVIR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ATRELEUTON; CANDESARTAN; COUMARIN ANTICOAGULANT; CV 15959; CYTOCHROME P450 2C9; DICLOFENAC; DRUG METABOLITE; DRUG METABOLIZING ENZYME; EPROSARTAN; GAVESTINEL; GLIPIZIDE; IRBESARTAN; LK 935; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OLMESARTAN; PARACETAMOL; PHENAZONE; PHENYTOIN; SULFONYLUREA DERIVATIVE; TASIMELTEON; TELMISARTAN; TOLBUTAMIDE; TR 14035; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; WARFARIN;

ARTICLE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME SPECIFICITY; GENE IDENTIFICATION; HUMAN; IN VIVO STUDY; LIPOPHILICITY; PHARMACOGENETICS; PHENOTYPE; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, GENETIC; SUBSTRATE SPECIFICITY; SULFONYLUREA COMPOUNDS; WARFARIN;

EID: 79951542454     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711794480131     Document Type: Article

References (293)

1. Zhou, S. F.; Zhou, Z. W.; Huang, M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 2010, 278, 165-188.
2. Zhou, S. F.; Di, Y. M.; Chan, E.; Du, Y. M.; Chow, V. D.; Xue, C. C.; Lai, X.; Wang, J. C.; Li, C. G.; Tian, M.; Duan, W. Clinical pharmacogenetics and potential application in personalized medicine. Curr. Drug Metab. 2008, 9, 738-784.
3. Rendic, S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 2002, 34, 83-448. (Pubitemid 34311090)
4. Zhou, S. F.; Zhou, Z. W.; Yang, L. P.; Cai, J. P. Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development. Curr. Med. Chem. 2009, 16, 3480-3675.
5. Sullivan-Klose, T. H.; Ghanayem, B. I.; Bell, D. A.; Zhang, Z. Y.; Kaminsky, L. S.; Shenfield, G. M.; Miners, J. O.; Birkett, D. J.; Goldstein, J. A. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996, 6, 341-349. (Pubitemid 26288624)
6. *3. Pharmacogenetics 1997, 7, 361-367. (Pubitemid 27427545)
7. Rettie, A. E.; Wienkers, L. C.; Gonzalez, F. J.; Trager, W. F.; Korzekwa, K. R. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994, 4, 39-42. (Pubitemid 24106122)
8. Imai, J.; Ieiri, I.; Mamiya, K.; Miyahara, S.; Furuumi, H.; Nanba, E.; Yamane, M.; Fukumaki, Y.; Ninomiya, H.; Tashiro, N.; Otsubo, K.; Higuchi, S. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 2000, 10, 85-89. (Pubitemid 30142817)
9. *5) expressed among African Americans. Mol. Pharmacol. 2001, 60, 382-387. (Pubitemid 32678304)
10. *11 in vivo among black Africans. Clin Pharmacol. Ther. 2004, 76, 113-118. (Pubitemid 39013401)
11. Allabi, A. C.; Gala, J. L.; Horsmans, Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet. Genomics 2005, 15, 779-786. (Pubitemid 41531727)
12. Kidd, R. S.; Curry, T. B.; Gallagher, S.; Edeki, T.; Blaisdell, J.; Goldstein, J. A. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001, 11, 803-808. (Pubitemid 33151515)
13. Rettie, A. E.; Farin, F. M.; Beri, N. G.; Srinouanprachanh, S. L.; Rieder, M. J.; Thijssen, H. H. A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9. Br. J. Clin. Pharmacol. 2006, 62, 617-620. (Pubitemid 44571584)
14. Si, D.; Guo, Y.; Zhang, Y.; Yang, L.; Zhou, H.; Zhong, D. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004, 14, 465-469. (Pubitemid 38971236)
15. Zhou, S. F.; Liu, J. P.; Chowbay, B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev. 2009, 41, 89-295.
16. Wang, B.; Wang, J.; Huang, S. Q.; Su, H. H.; Zhou, S. F. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr. Drug Metab. 2009, 10, 781-834.
17. Kamali, F.; Wynne, H. Pharmacogenetics of warfarin. Annu. Rev. Med. 2010, 61, 63-75.
18. Rosemary, J.; Adithan, C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr. Clin. Pharmacol. 2007, 2, 93-109. (Pubitemid 46729082)
19. Stehle, S.; Kirchheiner, J.; Lazar, A.; Fuhr, U. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin. Pharmacokinet. 2008, 47, 565-594.
20. Xu, H.; Murray, M.; McLachlan, A. J. Influence of genetic polymorphisms on the pharmacokinetics and pharmaco-dynamics of sulfonylurea drugs. Curr. Drug Metab. 2009, 10, 643-658.
21. Kirchheiner, J.; Brockmoller, J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 2005, 77, 1-16. (Pubitemid 40089477)
22. Rodrigues, A. D. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab. Dispos. 2005, 33, 1567-1575. (Pubitemid 41541940)
23. Catanzaro, D. F.; Frishman, W. H. Angiotensin receptor blockers for management of hypertension. South. Med. J. 2010, 103, 669-673.
24. Moen, M. D.; Wagstaff, A. J. Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy. Drugs 2005, 65, 2657-2674. (Pubitemid 43050959)
25. Stearns, R. A.; Chakravarty, P. K.; Chen, R.; Chiu, S. H. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: role of cytochrome P4502C and 3A subfamily members. Drug Metab. Dispos. 1995, 23, 207-215.
26. Yasar, U.; Tybring, G.; Hidestrand, M.; Oscarson, M.; Ingelman-Sundberg, M.; Dahl, M. L.; Eliasson, E. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab. Dispos. 2001, 29, 1051-1056. (Pubitemid 32605922)
27. Bourrie, M.; Meunier, V.; Berger, Y.; Fabre, G. Role of cytochrome P450 2C9 in irbesartan oxidation by human liver microsomes. Drug Metab. Dispos. 1999, 27, 288-296. (Pubitemid 29072087)
28. Chando, T. J.; Everett, D. W.; Kahle, A. D.; Starrett, A. M.; Vachharajani, N.; Shyu, W. C.; Kripalani, K. J.; Barbhaiya, R. H. Biotransformation of irbesartan in man. Drug Metab. Dispos. 1998, 26, 408-417. (Pubitemid 28223881)
29. 1 receptor antagonists. Clinical implications of active metabolites. J. Med. Chem. 2003, 46, 2261-2270. (Pubitemid 36637909)
30. 14C]telmisartan in healthy volunteers. J. Clin. Pharmacol. 2000, 40, 1312-1322.
31. Schwocho, L. R.; Masonson, H. N. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J. Clin. Pharmacol. 2001, 41, 515-527. (Pubitemid 32381869)
32. Ripley, T. L.; Chonlahan, J. S.; Germany, R. E. Candesartan in heart failure. Clin. Interv. Aging. 2006, 1, 357-366.
33. Mendis, B.; Page, S. R. Candesartan: widening indications for this angiotensin II receptor blocker? Expert Opin. Pharmacother. 2009, 10, 1995-2007.
34. Gleiter, C. H.; Morike, K. E. Clinical pharmacokinetics of candesartan. Clin Pharmacokinet. 2002, 41, 7-17. (Pubitemid 34158085)
35. *3 influences the metabolism and the druginteraction of candesartan in vitro. Pharmacogenomics J. 2001, 1, 288-292. (Pubitemid 33756653)
36. Uchida, S.; Watanabe, H.; Nishio, S.; Hashimoto, H.; Yamazaki, K.; Hayashi, H.; Ohashi, K. Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotype. Clin. Pharmacol. Ther. 2003, 74, 505-508. (Pubitemid 37357729)
37. Yun, C. H.; Lee, H. S.; Lee, H.; Rho, J. K.; Jeong, H. G.; Guengerich, F. P. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes: role of cytochrome P4503A (4) in formation of the active metabolite EXP3174. Drug Metab. Dispos. 1995, 23, 285-289.
38. Sica, D. A.; Gehr, T. W.; Ghosh, S. Clinical pharmacokinetics of losartan. Clin. Pharmacokinet. 2005, 44, 797-814. (Pubitemid 41126929)
39. Croom, K. F.; Plosker, G. L. Irbesartan: a review of its use in hypertension and diabetic nephropathy. Drugs 2008, 68, 1543-1569. (Pubitemid 352001192)
40. Davi, H.; Tronquet, C.; Miscoria, G.; Perrier, L.; DuPont, P.; Caix, J.; Simiand, J.; Berger, Y. Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques. Drug Metab. Dispos. 2000, 28, 79-88. (Pubitemid 30027516)
41. Marino, M. R.; Vachharajani, N. N. Drug interactions with irbesartan. Clin. Pharmacokinet. 2001, 40, 605-614. (Pubitemid 32758582)
42. Hallberg, P.; Karlsson, J.; Kurland, L.; Lind, L.; Kahan, T.; Malmqvist, K.; Ohman, K. P.; Nystrom, F.; Melhus, H. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J. Hypertens. 2002, 20, 2089-2093. (Pubitemid 35305508)
43. *3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur. J. Clin. Pharmacol. 2005, 61, 627-634.
44. Chen, G.; Jiang, S.; Mao, G.; Zhang, S.; Hong, X.; Tang, G.; Li, Z.; Liu, X.; Zhang, Y.; Xing, H.; Wang, B.; Yu, Y.; Xu, X. CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients. Methods Find. Exp. Clin. Pharmacol. 2006, 28, 19-24.
45. Wen, S. Y.; Wang, H.; Sun, O. J.; Wang, S. Q. Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray. World J. Gastroenterol. 2003, 9, 1342-1346. (Pubitemid 36805681)
46. Bramlage, P.; Schindler, C. Differences in pharmacology and their translation into differences in clinical efficacy-a comparison of the renin angiotensin blocking agents irbesartan and losartan. Expert Opin. Pharmacother. 2010, 11, 521-535.
47. Sachinidis, A.; Ko, Y.; Weisser, P.; Meyerzu Brickwedde, M. K.; Dusing, R.; Christian, R.; Wieczorek, A. J.; Vetter, H. EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells. J. Hypertens. 1993, 11, 155-162. (Pubitemid 23130568)
48. Lo, M. W.; Goldberg, M. R.; McCrea, J. B.; Lu, H.; Furtek, C. I.; Bjornsson, T. D. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin. Pharmacol. Ther. 1995, 58, 641-649. (Pubitemid 26018849)
49. Ohtawa, M.; Takayama, F.; Saitoh, K.; Yoshinaga, T.; Nakashima, M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br. J. Clin. Pharmacol. 1993, 35, 290-297. (Pubitemid 23074055)
50. Nakashima, M.; Umemura, K. The clinical pharmacology of losartan in Japanese subjects and patients. Blood Press. Suppl. 1996, 2, 62-66. (Pubitemid 26327106)
51. Sandwall, P.; Lo, M. W.; Jonzon, B.; Dalen, P.; Furtek, C.; Ritter, M.; Alvan, G.; McCrea, J.; Sjoqvist, F. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19). Eur. J. Clin. Pharmacol. 1999, 55, 279-283. (Pubitemid 29290919)
52. Kazierad, D. J.; Martin, D. E.; Blum, R. A.; Tenero, D. M.; Ilson, B.; Boike, S. C.; Etheredge, R.; Jorkasky, D. K. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin. Pharmacol. Ther. 1997, 62, 417-425. (Pubitemid 27475226)
53. Williamson, K. M.; Patterson, J. H.; McQueen, R. H.; Adams, K. F. Jr.; Pieper, J. A. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther. 1998, 63, 316-323. (Pubitemid 28182229)
54. Yasar, U.; Forslund-Bergengren, C.; Tybring, G.; Dorado, P.; Llerena, A.; Sjoqvist, F.; Eliasson, E.; Dahl, M. L. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin. Pharmacol. Ther. 2002, 71, 89-98. (Pubitemid 34124042)
55. *3 individuals. Pharmacotherapy 2003, 23, 720-725.
56. *3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur. J. Clin. Pharmacol. 2003, 59, 589-592. (Pubitemid 37494525)
57. Fischer, T. L.; Pieper, J. A.; Graff, D. W.; Rodgers, J. E.; Fischer, J. D.; Parnell, K. J.; Goldstein, J. A.; Greenwood, R.; Patterson, J. H. Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. Clin. Pharmacol. Ther. 2002, 72, 238-246.
58. Yin, T.; Maekawa, K.; Kamide, K.; Saito, Y.; Hanada, H.; Miyashita, K.; Kokubo, Y.; Akaiwa, Y.; Otsubo, R.; Nagatsuka, K.; Otsuki, T.; Horio, T.; Takiuchi, S.; Kawano, Y.; Minematsu, K.; Naritomi, H.; Tomoike, H.; Sawada, J.; Miyata, T. Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens. Res. 2008, 31, 1549-1557.
59. Babaoglu, M. O.; Yasar, U.; Sandberg, M.; Eliasson, E.; Dahl, M. L.; Kayaalp, S. O.; Bozkurt, A. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur. J. Clin. Pharmacol. 2004, 60, 337-342. (Pubitemid 39066253)
60. Wu, L.; Wang, X.; Xu, W.; Farzaneh, F.; Xu, R. The structure and pharmacological functions of coumarins and their derivatives. Curr. Med. Chem. 2009, 16, 4236-4260.
61. Rost, S.; Fregin, A.; Ivaskevicius, V.; Conzelmann, E.; Hortnagel, K.; Pelz, H. J.; Lappegard, K.; Seifried, E.; Scharrer, I.; Tuddenham, E. G.; Muller, C. R.; Strom, T. M.; Oldenburg, J. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency Type 2. Nature 2004, 427, 537-541. (Pubitemid 38209110)
62. Goodstadt, L.; Ponting, C. P. Vitamin K epoxide reductase: homology, active site and catalytic mechanism. Trends Biochem. Sci. 2004, 29, 289-292. (Pubitemid 38968759)
63. Ufer, M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin. Pharmacokinet. 2005, 44, 1227-1246. (Pubitemid 41832565)
64. Beinema, M.; Brouwers, J. R.; Schalekamp, T.; Wilffert, B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb. Haemost. 2008, 100, 1052-1057.
65. Ufer, M.; Svensson, J. O.; Krausz, K. W.; Gelboin, H. V.; Rane, A.; Tybring, G. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur. J. Clin. Pharmacol. 2004, 60, 173-182. (Pubitemid 38757128)
66. Manolopoulos, V. G.; Ragia, G.; Tavridou, A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics 2010, 11, 493-496.
67. Thijssen, H. H.; Flinois, J. P.; Beaune, P. H. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab. Dispos. 2000, 28, 1284-1290.
68. Perez-Andreu, V.; Roldan, V.; Lopez-Fernandez, M. F.; Anton, A. I.; Alberca, I.; Corral, J.; Montes, R.; Garcia-Barbera, N.; Ferrando, F.; Vicente, V.; Gonzalez-Conejero, R. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. J. Thromb. Haemost. 2010, 8, 1012-1017.
69. Verde, Z.; Ruiz, J. R.; Santiago, C.; Valle, B.; Bandres, F.; Calvo, E.; Lucia, A.; Gomez, G. F. A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. PLoS One 2010, 5, e11210.
70. *3 carriers. Clin. Pharmacol. Ther. 2004, 75, 394-402. (Pubitemid 38534560)
71. Schalekamp, T.; Brasse, B. P.; Roijers, J. F.; Chahid, Y.; van Geest-Daalderop, J. H.; de Vries-Goldschmeding, H.; van Wijk, E. M.; Egberts, A. C.; de Boer, A. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin. Pharmacol. Ther. 2006, 80, 13-22. (Pubitemid 43964915)
72. Saraeva, R. B.; Paskaleva, I. D.; Doncheva, E.; Eap, C. B.; Ganev, V. S. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements. J. Clin. Pharm. Ther. 2007, 32, 641-649. (Pubitemid 350135117)
73. *3 allele is associated with low dose requirement of acenocoumarol. Pharmacogenetics 2000, 10, 757-760.
74. Verstuyft, C.; Morin, S.; Robert, A.; Loriot, M. A.; Beaune, P.; Jaillon, P.; Becquemont, L. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics 2001, 11, 735-737. (Pubitemid 33078244)
75. Tassies, D.; Freire, C.; Pijoan, J.; Maragall, S.; Monteagudo, J.; Ordinas, A.; Reverter, J. C. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica 2002, 87, 1185-1191. (Pubitemid 35397778)
76. Cadamuro, J.; Dieplinger, B.; Felder, T.; Kedenko, I.; Mueller, T.; Haltmayer, M.; Patsch, W.; Oberkofler, H. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur. J. Clin. Pharmacol. 2010, 66, 253-260.
77. Teichert, M.; Eijgelsheim, M.; Rivadeneira, F.; Uitterlinden, A. G.; van Schaik, R. H.; Hofman, A.; De Smet, P. A.; van Gelder, T.; Visser, L. E.; Stricker, B. H. A genome-wide association study of acenocoumarol maintenance dosage. Hum. Mol. Genet. 2009, 18, 3758-3768.
78. *2 and VKORC1 c.-1639G> A, 497C> G, 1173C> T, and 3730G> A variants influence drug dose in anticoagulated patients. Thromb. Haemost. 2009, 101, 591-593.
79. Wijnen, P. A.; Linssen, C. F.; Haenen, G. R.; Bekers, O.; Drent, M. Variant VKORC1 and CYP2C9 alleles in patients with diffuse alveolar hemorrhage caused by oral anticoagulants. Mol. Diagn. Ther. 2010, 14, 23-30.
80. Markatos, C. N.; Grouzi, E.; Politou, M.; Gialeraki, A.; Merkouri, E.; Panagou, I.; Spiliotopoulou, I.; Travlou, A. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. Pharmacogenomics 2008, 9, 1631-1638.
81. *3. Clin. Pharmacol. Ther. 2001, 70, 292-298. (Pubitemid 32868494)
82. Thijssen, H. H.; Ritzen, B. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. Clin. Pharmacol. Ther. 2003, 74, 61-68. (Pubitemid 36776177)
83. Spreafico, M.; Lodigiani, C.; van Leeuwen, Y.; Pizzotti, D.; Rota, L. L.; Rosendaal, F.; Mannucci, P. M.; Peyvandi, F. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics 2008, 9, 1237-1250.
84. He, M.; Korzekwa, K. R.; Jones, J. P.; Rettie, A. E.; Trager, W. F. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch. Biochem. Biophys. 1999, 372, 16-28.
85. Ufer, M.; Kammerer, B.; Kahlich, R.; Kirchheiner, J.; Yasar, U.; Brockmoller, J.; Rane, A. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon S-7-hydroxylation in vitro and in vivo. Xenobiotica 2004, 34, 847-859. (Pubitemid 39546273)
86. Kirchheiner, J.; Ufer, M.; Walter, E. C.; Kammerer, B.; Kahlich, R.; Meisel, C.; Schwab, M.; Gleiter, C. H.; Rane, A.; Roots, I.; Brockmoller, J. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R-and S-phenprocoumon in healthy volunteers. Pharmacogenetics 2004, 14, 19-26. (Pubitemid 38183958)
87. Schalekamp, T.; Brasse, B. P.; Roijers, J. F.; van Meegen, E.; van der Meer, F. J.; van Wijk, E. M.; Egberts, A. C.; de Boer, A. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin. Pharmacol. Ther. 2007, 81, 185-193. (Pubitemid 46174815)
88. Werner, D.; Werner, U.; Wuerfel, A.; Grosch, A.; Lestin, H. G.; Eschenhagen, T.; Rau, T. Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing. Eur. J. Clin. Pharmacol. 2009, 65, 783-788.
89. Hummers-Pradier, E.; Hess, S.; Adham, I. M.; Papke, T.; Pieske, B.; Kochen, M. M. Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur. J. Clin. Pharmacol. 2003, 59, 213-219. (Pubitemid 36995130)
90. Schalekamp, T.; Oosterhof, M.; van Meegen, E.; van der Meer, F. J.; Conemans, J.; Hermans, M.; Meijerman, I.; de Boer, A. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin. Pharmacol. Ther. 2004, 76, 409-417. (Pubitemid 39469865)
91. *3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 2004, 14, 27-33. (Pubitemid 38183959)
92. *3 alleles on acenocoumarol or phenprocoumon. Thromb. Haemost. 2004, 92, 61-66. (Pubitemid 39010868)
93. Bovill, E. G.; Fung, M.; Cushman, M. Vitamin K and oral anticoagulation: thought for food. Am. J. Med. 2004, 116, 711-713. (Pubitemid 38581117)
94. Kuruvilla, M.; Gurk-Turner, C. A review of warfarin dosing and monitoring. Proc. (Bayl Univ Med Cent). 2001, 14, 305-306.
95. Kaminsky, L. S.; Zhang, Z. Y. Human P450 metabolism of warfarin. Pharmacol. Ther. 1997, 73, 67-74. (Pubitemid 26425815)
96. Hu, Z.; Yang, X.; Ho, P. C.; Chan, S. Y.; Heng, P. W.; Chan, E.; Duan, W.; Koh, H. L.; Zhou, S. Herb-drug interactions: a literature review. Drugs 2005, 65, 1239-1282. (Pubitemid 41038418)
97. Thi, L.; Shaw, D.; Bird, J. Warfarin potentiation: a review of the "FAB-4" significant drug interactions. Consult. Pharm. 2009, 24, 227-230.
98. Zhou, S. F.; Zhou, Z. W.; Li, C. G.; Chen, X.; Yu, X.; Xue, C. C.; Herington, A. Identification of drugs that interact with herbs in drug development. Drug Discov. Today 2007, 12, 664-673. (Pubitemid 47238642)
99. Higashi, M. K.; Veenstra, D. L.; Kondo, L. M.; Wittkowsky, A. K.; Srinouanprachanh, S. L.; Farin, F. M.; Rettie, A. E. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002, 287, 1690-1698. (Pubitemid 34289221)
100. Loebstein, R.; Yonath, H.; Peleg, D.; Almog, S.; Rotenberg, M.; Lubetsky, A.; Roitelman, J.; Harats, D.; Halkin, H.; Ezra, D. Interindividual variability in sensitivity to warfarin - Nature or nurture? Clin. Pharmacol. Ther. 2001, 70, 159-164.
101. Taube, J.; Halsall, D.; Baglin, T. Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of overanticoagulation in patients on long-term treatment. Blood 2000, 96, 1816-1819. (Pubitemid 30661066)
102. Herman, D.; Locatelli, I.; Grabnar, I.; Peternel, P.; Stegnar, M.; Mrhar, A.; Breskvar, K.; Dolzan, V. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J. 2005, 5, 193-202. (Pubitemid 40852221)
103. Takahashi, H.; Echizen, H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. 2001, 40, 587-603. (Pubitemid 32758581)
104. Takahashi, H.; Echizen, H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J. 2003, 3, 202-214. (Pubitemid 37167925)
105. Takahashi, H.; Wilkinson, G. R.; Nutescu, E. A.; Morita, T.; Ritchie, M. D.; Scordo, M. G.; Pengo, V.; Barban, M.; Padrini, R.; Ieiri, I.; Otsubo, K.; Kashima, T.; Kimura, S.; Kijima, S.; Echizen, H. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 2006, 16, 101-110. (Pubitemid 43145678)
106. Gage, B. F.; Eby, C.; Johnson, J. A.; Deych, E.; Rieder, M. J.; Ridker, P. M.; Milligan, P. E.; Grice, G.; Lenzini, P.; Rettie, A. E.; Aquilante, C. L.; Grosso, L.; Marsh, S.; Langaee, T.; Farnett, L. E.; Voora, D.; Veenstra, D. L.; Glynn, R. J.; Barrett, A.; McLeod, H. L. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 2008, 84, 326-331.
107. Schwarz, U. I.; Ritchie, M. D.; Bradford, Y.; Li, C.; Dudek, S. M.; Frye-Anderson, A.; Kim, R. B.; Roden, D. M.; Stein, CM. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 2008, 358, 999-1008. (Pubitemid 351347099)
108. Sanderson, S.; Emery, J.; Higgins, J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet. Med. 2005, 7, 97-104. (Pubitemid 40261834)
109. Aithal, G. P.; Day, C. P.; Kesteven, P. J. L.; Daly, A. K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999, 353, 717-719. (Pubitemid 29103806)
110. Scott, S. A.; Edelmann, L.; Kornreich, R.; Desnick, R. J. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am. J. Hum. Genet. 2008, 82, 495-500.
111. Wen, M. S.; Lee, M.; Chen, J. J.; Chuang, H. P.; Lu, L. S.; Chen, C. H.; Lee, T. H.; Kuo, C. T.; Sun, F. M.; Chang, Y. J.; Kuan, P. L.; Chen, Y. F.; Charng, M. J.; Ray, C. Y.; Wu, J. Y.; Chen, Y. T. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin. Pharmacol. Ther. 2008, 84, 83-89. (Pubitemid 351861488)
112. Borgiani, P.; Ciccacci, C.; Forte, V.; Romano, S.; Federici, G.; Novelli, G. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics 2007, 8, 1545-1550. (Pubitemid 350286398)
113. Wadelius, M.; Chen, L. Y.; Lindh, J. D.; Eriksson, N.; Ghori, M. J.; Bumpstead, S.; Holm, L.; McGinnis, R.; Rane, A.; Deloukas, P. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009, 113, 784-792.
114. Gu, Q.; Kong, Y.; Schneede, J.; Xiao, Y. B.; Chen, L.; Zhong, Q. J.; Wang, X. F.; Hao, J.; Chen, B. C.; Chen, J. J. VKORC1-1639G> A, CYP2C9, EPHX1691A> G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China. Eur. J. Clin. Pharmacol. 2010, 66, 1217-1227.
115. Takeuchi, F.; Kashida, M.; Okazaki, O.; Tanaka, Y.; Fukuda, S.; Kashima, T.; Hosaka, S.; Hiroe, M.; Kimura, S.; Kato, N. Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients. Circ. J. 2010, 74, 977-982.
116. Wells, P. S.; Majeed, H.; Kassem, S.; Langlois, N.; Gin, B.; Clermont, J.; Taljaard, M. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. Thromb. Res. 2010, 125, e259-264.
117. Cavallari, L. H.; Langaee, T. Y.; Momary, K. M.; Shapiro, N. L.; Nutescu, E. A.; Coty, W. A.; Viana, M. A.; Patel, S. R.; Johnson, J. A. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 2010, 87, 459-464.
118. Ferder, N. S.; Eby, C. S.; Deych, E.; Harris, J. K.; Ridker, P. M.; Milligan, P. E.; Goldhaber, S. Z.; King, C. R.; Giri, T.; McLeod, H. L.; Glynn, R. J.; Gage, B. F. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J. Thromb. Haemost. 2010, 8, 95-100.
119. Lindh, J. D.; Holm, L.; Andersson, M. L.; Rane, A. Influence of CYP2C9 genotype on warfarin dose requirements - a systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 2009, 65, 365-375.
120. Pautas, E.; Moreau, C.; Gouin-Thibault, I.; Golmard, J. L.; Mahe, I.; Legendre, C.; Taillandier-Heriche, E.; Durand-Gasselin, B.; Houllier, A. M.; Verrier, P.; Beaune, P.; Loriot, M. A.; Siguret, V. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin. Pharmacol. Ther. 2010, 87, 57-64.
121. Margaglione, M.; Colaizzo, D.; D'Andrea, G.; Brancaccio, V.; Ciampa, A.; Grandone, E.; Di Minno, G. Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost. 2000, 84, 775-778.
122. Lima, M. V.; Ribeiro, G. S.; Mesquita, E. T.; Victer, P. R.; Vianna-Jorge, R. CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients. Eur. J. Clin. Pharmacol. 2008, 64, 9-15.
123. Cramer, J. A.; Mintzer, S.; Wheless, J.; Mattson, R. H. Adverse effects of antiepileptic drugs: a brief overview of important issues. Expert Rev. Neurother. 2010, 10, 885-891.
124. Mintzer, S. Metabolic consequences of antiepileptic drugs. Curr Opin Neurol. 2010, 23, 164-169.
125. Klotz, U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin. Pharmacokinet. 2007, 46, 271-279. (Pubitemid 46507006)
126. Taylor, S.; Tudur Smith, C.; Williamson, P. R.; Marson, A. G. Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst. Rev. 2001, (4), CD002217.
127. Pustylnyak, V. O.; Gulyaeva, L. F.; Lyakhovich, V. V. Induction of cytochrome P4502B: role of regulatory elements and nuclear receptors. Biochemistry (Mosc) 2007, 72, 608-617. (Pubitemid 47142360)
128. Yamada, H.; Ishii, Y.; Yamamoto, M.; Oguri, K. Induction of the hepatic cytochrome P450 2B subfamily by xenobiotics: research history, evolutionary aspect, relation to tumorigenesis, and mechanism. Curr. Drug Metab. 2006, 7, 397-409.
129. Goto, S.; Seo, T.; Murata, T.; Nakada, N.; Ueda, N.; Ishitsu, T.; Nakagawa, K. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese. Ther. Drug Monit. 2007, 29, 118-121. (Pubitemid 46279885)
130. Graves, N. M. Pharmacokinetics and interactions of antiepileptic drugs. Am. J. Hosp. Pharm. 1993, 50, S23-29; (Pubitemid 23357825)
131. quiz S30-22.
132. Yamanaka, H.; Nakajima, M.; Hara, Y.; Katoh, M.; Tachibana, O.; Yamashita, J.; Yokoi, T. Urinary excretion of phenytoin metabolites, 5-(4'-hydroxyphenyl)-5-phenylhydantoin and its O-glucuronide in humans and
133. Bajpai, M.; Roskos, L. K.; Shen, D. D.; Levy, R. H. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab. Dispos. 1996, 24, 1401-1403. (Pubitemid 26427180)
134. Nakajima, M.; Sakata, N.; Ohashi, N.; Kume, T.; Yokoi, T. Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes. Drug Metab. Dispos. 2002, 30, 1250-1256. (Pubitemid 35265833)
135. Odani, A.; Hashimoto, Y.; Otsuki, Y.; Uwai, Y.; Hattori, H.; Furusho, K.; Inui, K. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin. Pharmacol. Ther. 1997, 62, 287-292. (Pubitemid 27417794)
136. *3 allele. Pharmacogenetics 1999, 9, 71-80. (Pubitemid 29176726)
137. Aynacioglu, A. S.; Brockmoller, J.; Bauer, S.; Sachse, C.; Guzelbey, P.; Ongen, Z.; Nacak, M.; Roots, I. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br. J. Clin. Pharmacol. 1999, 48, 409-415. (Pubitemid 29417726)
138. Warner, A.; Privitera, M.; Bates, D. Standards of laboratory practice: antiepileptic drug monitoring. Natl. Acad. Clin. Biochem. Clin. Chem. 1998, 44, 1085-1095. (Pubitemid 28213157)
139. Caraco, Y.; Muszkat, M.; Wood, A. J. Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. Pharmacogenetics 2001, 11, 587-596. (Pubitemid 32953584)
140. van der Weide, J.; Steijns, L. S.; van Weelden, M. J.; de Haan, K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001, 11, 287-291. (Pubitemid 32537401)
141. Mamiya, K.; Ieiri, I.; Shimamoto, J.; Yukawa, E.; Imai, J.; Ninomiya, H.; Yamada, H.; Otsubo, K.; Higuchi, S.; Tashiro, N. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 1998, 39, 1317-1323. (Pubitemid 29005631)
142. Hung, C. C.; Lin, C. J.; Chen, C. C.; Chang, C. J.; Liou, H. H. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther. Drug Monit. 2004, 26, 534-540.
143. Kesavan, R.; Narayan, S. K.; Adithan, C. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur. J. Clin. Pharmacol. 2010, 66, 689-696.
144. Soga, Y.; Nishimura, F.; Ohtsuka, Y.; Araki, H.; Iwamoto, Y.; Naruishi, H.; Shiomi, N.; Kobayashi, Y.; Takashiba, S.; Shimizu, K.; Gomita, Y.; Oka, E. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Sci. 2004, 74, 827-834. (Pubitemid 37501131)
145. Lee, A. Y.; Kim, M. J.; Chey, W. Y.; Choi, J.; Kim, B. G. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoininduced cutaneous adverse drug reactions. Eur. J. Clin. Pharmacol. 2004, 60, 155-159. (Pubitemid 38757125)
146. Zhang, X. Z.; Li, X. J.; Zhang, H. Y. Valproic acid as a promising agent to combat Alzheimer's disease. Brain Res. Bull. 2010, 81, 3-6.
147. Kumar, S.; Wong, H.; Yeung, S. A.; Riggs, K. W.; Abbott, F. S.; Rurak, D. W. Disposition of valproic acid in maternal, fetal, and newborn sheep. II: metabolism and renal elimination. Drug Metab. Dispos. 2000, 28, 857-864. (Pubitemid 30470836)
148. Sadeque, A. J.; Fisher, M. B.; Korzekwa, K. R.; Gonzalez, F. J.; Rettie, A. E. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J. Pharmacol. Exp. Ther. 1997, 283, 698-703. (Pubitemid 27514629)
149. Levy, R. H.; Rettenmeier, A. W.; Anderson, G. A.; Wilensky, A. J.; Friel, P. N.; Baillie, T. A.; Acheampong, A.; Tor, J.; Guyot, M.; Loiseau, P. Effects of polytherapy with phenytoin carbamazepine and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin. Pharmacol. Ther. 1990, 48, 225-235. (Pubitemid 20323648)
150. Gopaul, S. V.; Farrell, K.; Abbott, F. S. Identification and characterization of N-acetylcysteine conjugates of valproic acid in humans and animals. Drug Metab. Dispos. 2000, 28, 823-832. (Pubitemid 30470833)
151. Jiang, D.; Bai, X.; Zhang, Q.; Lu, W.; Wang, Y.; Li, L.; Muller, M. Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling. Eur. J. Clin. Pharmacol. 2009, 65, 1187-1193.
152. Tan, L.; Yu, J. T.; Sun, Y. P.; Ou, J. R.; Song, J. H.; Yu, Y. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin. Neurol. Neurosurg. 2010, 112, 320-323.
153. Phillips, P. J.; Twigg, S. M. Oral hypoglycaemics - a review of the evidence. Aust. Fam. Physician 2010, 39, 651-653.
154. Kokil, G. R.; Rewatkar, P. V.; Verma, A.; Thareja, S.; Naik, S. R. Pharmacology and chemistry of diabetes mellitus and antidiabetic drugs: A critical review. Curr. Med. Chem. 2010, 17(35), 4405-4423.
155. Aittoniemi, J.; Fotinou, C.; Craig, T. J.; de Wet, H.; Proks, P.; Ashcroft, F. M. Review. SUR1: a unique ATP-binding cassette protein that functions as an ion channel regulator. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2009, 364, 257-267.
156. ATP channelopathies in the pancreas. Pflugers Arch. 2010, 460, 307-320.
157. ATP channel. Circ. Res. 2008, 102, 164-176. (Pubitemid 351651120)
158. Shon, J. H.; Yoon, Y. R.; Kim, M. J.; Kim, K. A.; Lim, Y. C.; Liu, K. H.; Shin, D. H.; Lee, C. H.; Cha, I. J.; Shin, J. G. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br. J. Clin. Pharmacol. 2005, 59, 552-563. (Pubitemid 40632246)
159. Kimber-Trojnar, Z.; Marciniak, B.; Leszczynska-Gorzelak, B.; Trojnar, M.; Oleszczuk, J. Glyburide for the treatment of gestational diabetes mellitus. Pharmacol. Rep. 2008, 60, 308-318.
160. Rydberg, T.; Jonsson, A.; Melander, A. Comparison of the kinetics of glyburide and its active metabolites in humans. J. Clin. Pharm. Ther. 1995, 20, 283-295.
161. Zharikova, O. L.; Ravindran, S.; Nanovskaya, T. N.; Hill, R. A.; Hankins, G. D.; Ahmed, M. S. Kinetics of glyburide metabolism by hepatic and placental microsomes of human and baboon. Biochem. Pharmacol. 2007, 73, 2012-2019. (Pubitemid 46677903)
162. Naritomi, Y.; Terashita, S.; Kagayama, A. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica 2004, 34, 415-427. (Pubitemid 38901452)
163. *3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects. Yao Xue Xue Bao 2005, 40, 796-799. (Pubitemid 41551665)
164. Niemi, M.; Cascorbi, I.; Timm, R.; Kroemer, H. K.; Neuvonen, P. J.; Kivisto, K. T. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin. Pharmacol. Ther. 2002, 72, 326-332.
165. Kirchheiner, J.; Brockmoller, J.; Meineke, I.; Bauer, S.; Rohde, W.; Meisel, C.; Roots, I. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin. Pharmacol. Ther. 2002, 71, 286-296. (Pubitemid 34311458)
166. Yin, O. Q.; Tomlinson, B.; Chow, M. S. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin. Pharmacol. Ther. 2005, 78, 370-377. (Pubitemid 41393672)
167. Elliot, D. J.; Suharjono; Lewis, B. C.; Gillam, E. M.; Birkett, D. J.; Gross, A. S.; Miners, J. O. Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. Br. J. Clin. Pharmacol. 2007, 64, 450-457. (Pubitemid 47404317)
168. Zhang, Y.; Si, D.; Chen, X.; Lin, N.; Guo, Y.; Zhou, H.; Zhong, D. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. Br. J. Clin. Pharmacol. 2007, 64, 67-74. (Pubitemid 46934414)
169. Wang, R.; Chen, K.; Wen, S. Y.; Li, J.; Wang, S. Q. Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clin. Pharmacol. Ther. 2005, 78, 90-92. (Pubitemid 40956936)
170. Suzuki, K.; Yanagawa, T.; Shibasaki, T.; Kaniwa, N.; Hasegawa, R.; Tohkin, M. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with Type 2 diabetes. Diabetes Res. Clin. Pract. 2006, 72, 148-154.
171. Abad, S.; Moachon, L.; Blanche, P.; Bavoux, F.; Sicard, D.; Salmon-Ceron, D. Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia. Br. J. Clin. Pharmacol. 2001, 52, 456-457. (Pubitemid 32939450)
172. Tan, B.; Zhang, Y. F.; Chen, X. Y.; Zhao, X. H.; Li, G. X.; Zhong, D. F. The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects. Eur. J. Clin. Pharmacol. 2010, 66, 145-151.
173. Tentolouris, N.; Voulgari, C.; Katsilambros, N. A review of nateglinide in the management of patients with Type 2 diabetes. Vasc. Health Risk Manag. 2007, 3, 797-807.
174. McLeod, J. F. Clinical pharmacokinetics of nateglinide: a rapidlyabsorbed, short-acting insulinotropic agent. Clin. Pharmacokinet. 2004, 43, 97-120. (Pubitemid 38283133)
175. Weaver, M. L.; Orwig, B. A.; Rodriguez, L. C.; Graham, E. D.; Chin, J. A.; Shapiro, M. J.; McLeod, J. F.; Mangold, J. B. Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab. Dispos. 2001, 29, 415-421. (Pubitemid 32275555)
176. Kirchheiner, J.; Meineke, I.; Muller, G.; Bauer, S.; Rohde, W.; Meisel, C.; Roots, I.; Brockmoller, J. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin. Pharmacokinet. 2004, 43, 267-278. (Pubitemid 38429306)
177. Wester, M. R.; Lasker, J. M.; Johnson, E. F.; Raucy, J. L. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab. Dispos. 2000, 28, 354-359. (Pubitemid 30137062)
178. Kirchheiner, J.; Bauer, S.; Meineke, I.; Rohde, W.; Prang, V.; Meisel, C.; Roots, I.; Brockmoller, J. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002, 12, 101-109. (Pubitemid 34298914)
179. Shon, J. H.; Yoon, Y. R.; Kim, K. A.; Lim, Y. C.; Lee, K. J.; Park, J. Y.; Cha, I. J.; Flockhart, D. A.; Shin, J. G. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 2002, 12, 111-119. (Pubitemid 34298915)
180. *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin. Pharmacol. Ther. 2008, 83, 288-292.
181. *1 heterozygotes. Clin. Pharmacol. Ther. 2002, 72, 562-571. (Pubitemid 36237728)
182. Chen, K.; Wang, R.; Wen, S. Y.; Li, J.; Wang, S. Q. Relationship of P450 2C9 genetic polymorphisms in Chinese and the pharmacokinetics of tolbutamide. J. Clin. Pharm. Ther. 2005, 30, 241-249. (Pubitemid 41603047)
183. Vivas, D.; Angiolillo, D. J. Platelet P2Y receptor inhibition: an update on clinical drug development. Am. J. Cardiovasc. Drugs 2010, 10, 217-226.
184. Farid, N. A.; Kurihara, A.; Wrighton, S. A. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J. Clin. Pharmacol. 2010, 50, 126-142.
185. Laizure, S. C.; Parker, R. B. A comparison of the metabolism of clopidogrel and prasugrel. Expert Opin. Drug Metab. Toxicol. 2010, 6, 1417-1424.
186. Kazui, M.; Nishiya, Y.; Ishizuka, T.; Hagihara, K.; Farid, N. A.; Okazaki, O.; Ikeda, T.; Kurihara, A. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos. 2010, 38, 92-99.
187. Clarke, T. A.; Waskell, L. A. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab. Dispos. 2003, 31, 53-59. (Pubitemid 36735258)
188. Brandt, J. T.; Close, S. L.; Iturria, S. J.; Payne, C. D.; Farid, N. A.; Ernest, C. S. 2nd; Lachno, D. R.; Salazar, D.; Winters, K. J. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 2007, 5, 2429-2436. (Pubitemid 350154353)
189. Shuldiner, A. R.; O'Connell, J. R.; Bliden, K. P.; Gandhi, A.; Ryan, K.; Horenstein, R. B.; Damcott, C. M.; Pakyz, R.; Tantry, U. S.; Gibson, Q.; Pollin, T. I.; Post, W.; Parsa, A.; Mitchell, B. D.; Faraday, N.; Herzog, W.; Gurbel, P. A. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009, 302, 849-857.
190. Hulot, J. S.; Bura, A.; Villard, E.; Azizi, M.; Remones, V.; Goyenvalle, C.; Aiach, M.; Lechat, P.; Gaussem, P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006, 108, 2244-2247. (Pubitemid 44497506)
191. Frere, C.; Cuisset, T.; Morange, P. E.; Quilici, J.; Camoin-Jau, L.; Saut, N.; Faille, D.; Lambert, M.; Juhan-Vague, I.; Bonnet, J. L.; Alessi, M. C. Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am. J. Cardiol. 2008, 101, 1088-1093.
192. Simon, T.; Verstuyft, C.; Mary-Krause, M.; Quteineh, L.; Drouet, E.; Meneveau, N.; Steg, P. G.; Ferrieres, J.; Danchin, N.; Becquemont, L. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 2009, 360, 363-375.
193. Kim, K. A.; Park, P. W.; Hong, S. J.; Park, J. Y. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin. Pharmacol. Ther. 2008, 84, 236-242.
194. Umemura, K.; Furuta, T.; Kondo, K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J. Thromb. Haemost. 2008, 6, 1439-1441. (Pubitemid 352016331)
195. Mega, J. L.; Close, S. L.; Wiviott, S. D.; Shen, L.; Hockett, R. D.; Brandt, J. T.; Walker, J. R.; Antman, E. M.; Macias, W.; Braunwald, E.; Sabatine, M. S. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 2009, 360, 354-362.
196. Collet, J. P.; Hulot, J. S.; Pena, A.; Villard, E.; Esteve, J. B.; Silvain, J.; Payot, L.; Brugier, D.; Cayla, G.; Beygui, F.; Bensimon, G.; Funck-Brentano, C.; Montalescot, G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009, 373, 309-317.
197. Fontana, P.; Hulot, J. S.; De Moerloose, P.; Gaussem, P. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J. Thromb. Haemost. 2007, 5, 2153-2155. (Pubitemid 47450038)
198. Chen, B. L.; Zhang, W.; Li, Q.; Li, Y. L.; He, Y. J.; Fan, L.; Wang, L. S.; Liu, Z. Q.; Zhou, H. H. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms. Clin. Exp. Pharmacol. Physiol. 2008, 35, 904-908. (Pubitemid 351953054)
199. Giusti, B.; Gori, A. M.; Marcucci, R.; Saracini, C.; Sestini, I.; Paniccia, R.; Valente, S.; Antoniucci, D.; Abbate, R.; Gensini, G. F. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet. Genomics 2007, 17, 1057-1064. (Pubitemid 351339490)
200. 12 receptor antagonist. Methods Mol. Biol. 2010, 663, 221-228.
201. Angiolillo, D. J.; Bates, E. R.; Bass, T. A. Clinical profile of prasugrel, a novel thienopyridine. Am. Heart J. 2008, 156, S16-22.
202. Williams, E. T.; Jones, K. O.; Ponsler, G. D.; Lowery, S. M.; Perkins, E. J.; Wrighton, S. A.; Ruterbories, K. J.; Kazui, M.; Farid, N. A. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab. Dispos. 2008, 36, 1227-1232. (Pubitemid 351929304)
203. Niitsu, Y.; Jakubowski, J. A.; Sugidachi, A.; Asai, F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin. Thromb. Hemost. 2005, 31, 184-194. (Pubitemid 40605193)
204. Farid, N. A.; Smith, R. L.; Gillespie, T. A.; Rash, T. J.; Blair, P. E.; Kurihara, A.; Goldberg, M. J. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab. Dispos. 2007, 35, 1096-1104. (Pubitemid 46956429)
205. Wickremsinhe, E. R.; Tian, Y.; Ruterbories, K. J.; Verburg, E. M.; Weerakkody, G. J.; Kurihara, A.; Farid, N. A. Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method. Drug Metab. Dispos. 2007, 35, 917-921. (Pubitemid 46798602)
206. Frelinger, A. L. 3rd; Jakubowski, J. A.; Li, Y.; Barnard, M. R.; Linden, M. D.; Tarnow, I.; Fox, M. L.; Sugidachi, A.; Winters, K. J.; Furman, M. I.; Michelson, A. D. The active metabolite of prasugrel inhibits adenosine diphosphate-and collagen-stimulated platelet procoagulant activities. J. Thromb. Haemost. 2008, 6, 359-365.
207. Judge, H. M.; Buckland, R. J.; Sugidachi, A.; Jakubowski, J. A.; Storey, R. F. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and proinflammatory platelet responses. Platelets 2008, 19, 125-133. (Pubitemid 351302377)
208. Rehmel, J. L.; Eckstein, J. A.; Farid, N. A.; Heim, J. B.; Kasper, S. C.; Kurihara, A.; Wrighton, S. A.; Ring, B. J. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab. Dispos. 2006, 34, 600-607.
209. Mega, J. L.; Close, S. L.; Wiviott, S. D.; Shen, L.; Hockett, R. D.; Brandt, J. T.; Walker, J. R.; Antman, E. M.; Macias, W. L.; Braunwald, E.; Sabatine, M. S. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009, 119, 2553-2560.
210. Ha-Duong, N. T.; Dijols, S.; Macherey, A. C.; Goldstein, J. A.; Dansette, P. M.; Mansuy, D. Ticlopidine as a selective mechanismbased inhibitor of human cytochrome P450 2C19. Biochemistry 2001, 40, 12112-12122. (Pubitemid 32946552)
211. Dalvie, D. K.; O'Connell, T. N. Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes P450, and monoamine oxidases. Drug Metab. Dispos. 2004, 32, 49-57. (Pubitemid 38112535)
212. Mano, Y.; Usui, T.; Kamimura, H. Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Drug Metab. Dispos. 2007, 35, 1182-1187. (Pubitemid 46956440)
213. el Mouelhi, M.; Beck, S.; Bock, K. W. Stereoselective glucuronidation of (R) - and (S)-naproxen by recombinant rat phenol UDP-glucuronosyltransferase (UGT1A1) and its human orthologue. Biochem. Pharmacol. 1993, 46, 1298-1300. (Pubitemid 23306752)
214. Kuehl, G. E.; Lampe, J. W.; Potter, J. D.; Bigler, J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab. Dispos. 2005, 33, 1027-1035. (Pubitemid 41002785)
215. Mano, Y.; Usui, T.; Kamimura, H. Contribution of UDP- glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur. J. Clin. Pharmacol. 2007, 63, 289-296. (Pubitemid 46233157)
216. Mano, Y.; Usui, T.; Kamimura, H. Identification of human UDP-glucuronosyltransferase responsible for the glucuronidation of niflumic acid in human liver. Pharm. Res. 2006, 23, 1502-1508. (Pubitemid 43993813)
217. Murakami, N.; Takase, H.; Tomita, T.; Iwata, K.; Naruse, T. Antinociceptive activity of a novel non-steroidal anti-inflammatory drug (M-5011) with low ulcerogenic effects in mice. Jpn. J. Pharmacol. 1996, 72, 29-37. (Pubitemid 26345519)
218. Taguchi, K.; Konishi, T.; Nishikawa, H.; Kitamura, S. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl) phenyl]propionic acid. Xenobiotica 1999, 29, 899-907. (Pubitemid 29454383)
219. Leemann, T. D.; Transon, C.; Bonnabry, P.; Dayer, P. A major role for cytochrome P450TB (CYP2C subfamily) in the actions of nonsteroidal antiinflammatory drugs. Drugs Exp. Clin. Res. 1993, 19, 189-195. (Pubitemid 24029190)
220. Hamman, M. A.; Haehner-Daniels, B. D.; Wrighton, S. A.; Rettie, A. E.; Hall, S. D. Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases: comparison of human liver and kidney microsomes and mammalian enzymes. Biochem. Pharmacol. 2000, 60, 7-17. (Pubitemid 30243080)
221. Chakraborti, A. K.; Garg, S. K.; Kumar, R.; Motiwala, H. F.; Jadhavar, P. S. Progress in COX-2 inhibitors: a journey so far. Curr. Med. Chem. 2010, 17, 1563-1593.
222. Sandberg, M.; Yasar, U.; Stromberg, P.; Hoog, J. O.; Eliasson, E. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br. J. Clin. Pharmacol. 2002, 54, 423-429. (Pubitemid 35334956)
223. 14C-celecoxib in healthy male volunteers. Drug Metab. Dispos. 2000, 28, 308-314. (Pubitemid 30137055)
224. Tang, C.; Shou, M.; Rushmore, T. H.; Mei, Q.; Sandhu, P.; Woolf, E. J.; Rose, M. J.; Gelmann, A.; Greenberg, H. E.; De Lepeleire, I.; Van Hecken, A.; De Schepper, P. J.; Ebel, D. L.; Schwartz, J. I.; Rodrigues, A. D. In vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in vivo pharmacokinetics. Pharmacogenetics 2001, 11, 223-235. (Pubitemid 32319872)
225. Werner, U.; Werner, D.; Pahl, A.; Mundkowski, R.; Gillich, M.; Brune, K. Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. Biomed. Chromatogr. 2002, 16, 56-60. (Pubitemid 34121395)
226. Kirchheiner, J.; Stormer, E.; Meisel, C.; Steinbach, N.; Roots, I.; Brockmoller, J. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 2003, 13, 473-480. (Pubitemid 37034589)
227. Stempak, D.; Bukaveckas, B. L.; Linder, M.; Koren, G.; Baruchel, S. Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient. Clin. Pharmacol. Ther. 2005, 78, 309-310. (Pubitemid 41254115)
228. *3. Clin. Pharmacol. Ther. 2006, 79, 287-288.
229. Brenner, S. S.; Herrlinger, C.; Dilger, K.; Murdter, T. E.; Hofmann, U.; Marx, C.; Klotz, U. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin. Pharmacokinet. 2003, 42, 283-292. (Pubitemid 36308065)
230. Shen, S.; Marchick, M. R.; Davis, M. R.; Doss, G. A.; Pohl, L. R. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem. Res. Toxicol. 1999, 12, 214-222. (Pubitemid 29096071)
231. *3 allele. Eur. J. Clin. Pharmacol. 2000, 56, 65-68. (Pubitemid 30317784)
232. Morin, S.; Loriot, M. A.; Poirier, J. M.; Tenneze, L.; Beaune, P. H.; Funck-Brentano, C.; Jaillon, P.; Becquemont, L. Is diclofenac a valuable CYP2C9 probe in humans? Eur. J. Clin. Pharmacol. 2001, 56, 793-797. (Pubitemid 33788550)
233. Yasar, U.; Eliasson, E.; Forslund-Bergengren, C.; Tybring, G.; Gadd, M.; Sjoqvist, F.; Dahl, M. L. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur. J. Clin. Pharmacol. 2001, 57, 729-735. (Pubitemid 34031266)
234. Yamazaki, H.; Inoue, K.; Chiba, K.; Ozawa, N.; Kawai, T.; Suzuki, Y.; Goldstein, J. A.; Guengerich, F. P.; Shimada, T. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cysand Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem. Pharmacol. 1998, 56, 243-251. (Pubitemid 28479833)
235. Tang, W.; Stearns, R. A.; Wang, R. W.; Chiu, S. H.; Baillie, T. A. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem. Res. Toxicol. 1999, 12, 192-199. (Pubitemid 29096068)
236. Aithal, G. P.; Day, C. P.; Leathart, J. B.; Daly, A. K. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenacinduced hepatitis. Pharmacogenetics 2000, 10, 511-518.
237. Kirchheiner, J.; Meineke, I.; Steinbach, N.; Meisel, C.; Roots, I.; Brockmoller, J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br. J. Clin. Pharmacol. 2003, 55, 51-61. (Pubitemid 36110839)
238. Dorado, P.; Berecz, R.; Norberto, M. J.; Yasar, U.; Dahl, M. L.; A, L. L. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur. J. Clin. Pharmacol. 2003, 59, 221-225. (Pubitemid 37009744)
239. Dorado, P.; Cavaco, I.; Caceres, M. C.; Piedade, R.; Ribeiro, V.; Llerena, A. Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. Eur. J. Clin. Pharmacol. 2008, 64, 967-970.
240. Tracy, T. S.; Rosenbluth, B. W.; Wrighton, S. A.; Gonzalez, F. J.; Korzekwa, K. R. Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of R-and S-flurbiprofen. Biochem. Pharmacol. 1995, 49, 1269-1275.
241. *3 genotypes. Eur. J. Clin. Pharmacol. 2003, 58, 791-794.
242. Pierce, C. A.; Voss, B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann. Pharmacother. 2010, 44, 489-506.
243. Hamman, M. A.; Thompson, G. A.; Hall, S. D. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem. Pharmacol. 1997, 54, 33-41. (Pubitemid 27353220)
244. Chang, S. Y.; Li, W.; Traeger, S. C.; Wang, B.; Cui, D.; Zhang, H.; Wen, B.; Rodrigues, A. D. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in S-(+) - and R-(-)-ibuprofen hydroxylation in vitro. Drug Metab. Dispos. 2008, 36, 2513-2522.
245. Kirchheiner, J.; Meineke, I.; Freytag, G.; Meisel, C.; Roots, I.; Brockmoller, J. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin. Pharmacol. Ther. 2002, 72, 62-75. (Pubitemid 34833188)
246. Martinez, C.; Garcia-Martin, E.; Blanco, G.; Gamito, F. J.; Ladero, J. M.; Agundez, J. A. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br. J. Clin. Pharmacol. 2005, 59, 62-69.
247. Garcia-Martin, E.; Martinez, C.; Tabares, B.; Frias, J.; Agundez, J. A. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin. Pharmacol. Ther. 2004, 76, 119-127. (Pubitemid 39013402)
248. Lopez-Rodriguez, R.; Novalbos, J.; Gallego-Sandin, S.; Roman-Martinez, M.; Torrado, J.; Gisbert, J. P.; Abad-Santos, F. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers. Pharmacol. Res. 2008, 58, 77-84.
249. Durrmeyer, X.; Hovhannisyan, S.; Medard, Y.; Jacqz-Aigrain, E.; Decobert, F.; Barre, J.; Alberti, C.; Aujard, Y.; Danan, C.; Baud, O. Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants? PLoS One 2010, 5, e12329.
250. Bonnabry, P.; Leemann, T.; Dayer, P. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur. J. Clin. Pharmacol. 1996, 49, 305-308. (Pubitemid 26037157)
251. Takanashi, K.; Tainaka, H.; Kobayashi, K.; Yasumori, T.; Hosakawa, M.; Chiba, K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000, 10, 95-104. (Pubitemid 30193071)
252. *13. Xenobiotica 2005, 35, 853-861. (Pubitemid 41759171)
253. Zhang, Y.; Zhong, D.; Si, D.; Guo, Y.; Chen, X.; Zhou, H. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br. J. Clin. Pharmacol. 2005, 59, 14-17. (Pubitemid 40044795)
254. *13) in the metabolism of lornoxicam in humans. Drug Metab. Dispos. 2005, 33, 749-753. (Pubitemid 40686627)
255. *3 allele on lornoxicam metabolism. Clin. Chim. Acta 2006, 364, 287-291. (Pubitemid 43124018)
256. Buvanendran, A.; Barkin, R. Lumiracoxib. Drugs Today (Barc) 2007, 43, 137-147. (Pubitemid 46658569)
257. Mangold, J. B.; Gu, H.; Rodriguez, L. C.; Bonner, J.; Dickson, J.; Rordorf, C. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab. Dispos. 2004, 32, 566-571. (Pubitemid 38535036)
258. Li, Y.; Slatter, J. G.; Zhang, Z.; Li, Y.; Doss, G. A.; Braun, M. P.; Stearns, R. A.; Dean, D. C.; Baillie, T. A.; Tang, W. In vitro metabolic activation of lumiracoxib in rat and human liver preparations. Drug Metab. Dispos. 2008, 36, 469-473. (Pubitemid 351185763)
259. Fendrick, A. M.; Greenberg, B. P. A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritis. Osteopath. Med. Prim. Care 2009, 3, 1.
260. Kiang, C. H.; Lee, C.; Kushinsky, S. Isolation and identification of 6-desmethylnaproxen sulfate as a new metabolite of naproxen in human plasma. Drug Metab. Dispos. 1989, 17, 43-48. (Pubitemid 19058162)
261. Tracy, T. S.; Marra, C.; Wrighton, S. A.; Gonzalez, F. J.; Korzekwa, K. R. Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur. J. Clin. Pharmacol. 1997, 52, 293-298. (Pubitemid 27283297)
262. *3 allele on the pharmacokinetics of naproxen in Korean subjects. Arch. Pharm. Res. 2009, 32, 269-273.
263. *5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab. Dispos. 2002, 30, 385-390. (Pubitemid 34263822)
264. Perini, J. A.; Vianna-Jorge, R.; Brogliato, A. R.; Suarez-Kurtz, G. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clin. Pharmacol. Ther. 2005, 78, 362-369. (Pubitemid 41393671)
265. *3 allele in a tenoxicam bioequivalence study performed on Spaniards. Pharmacol. Res. 2009, 59, 62-68.
266. Scripture, C. D.; Pieper, J. A. Clinical pharmacokinetics of fluvastatin. Clin. Pharmacokinet. 2001, 40, 263-281. (Pubitemid 32458153)
267. Fischer, V.; Johanson, L.; Heitz, F.; Tullman, R.; Graham, E.; Baldeck, J. P.; Robinson, W. T. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P450 and implications for metabolic drug interactions. Drug Metab. Dispos. 1999, 27, 410-416. (Pubitemid 29114251)
268. Zhou, S. F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab. 2008, 9, 310-322.
269. Kirchheiner, J.; Kudlicz, D.; Meisel, C.; Bauer, S.; Meineke, I.; Roots, I.; Brockmoller, J. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-) - 3S, 5R-fluvastatin and (+)-3R, 5S-fluvastatin in healthy volunteers. Clin. Pharmacol. Ther. 2003, 74, 186-194. (Pubitemid 36951816)
270. Hewitt, D. J. The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin. J. Pain. 2000, 16, S73-79. (Pubitemid 30395248)
271. Sundstrom, I.; Hedeland, M.; Bondesson, U.; Andren, P. E. Identification of glucuronide conjugates of ketobemidone and its phase I metabolites in human urine utilizing accurate mass and tandem time-of-flight mass spectrometry. J. Mass Spectrom. 2002, 37, 414-420. (Pubitemid 34413911)
272. Sundstrom, I.; Bondesson, U.; Hedeland, M. Identification of Phase I and Phase II metabolites of ketobemidone in patient urine using liquid chromatography-electrospray tandem mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 2001, 763, 121-131. (Pubitemid 32972311)
273. Yasar, U.; Annas, A.; Svensson, J. O.; Lazorova, L.; Artursson, P.; Al-Shurbaji, A. Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica 2005, 35, 785-796. (Pubitemid 41665515)
274. Elkashef, A.; Vocci, F.; Huestis, M.; Haney, M.; Budney, A.; Gruber, A.; el-Guebaly, N. Marijuana neurobiology and treatment. Subst. Abus. 2008, 29, 17-29.
275. Mackie, K. Cannabinoid receptors: where they are and what they do. J. Neuroendocrinol. 2008, 20 (Suppl 1), 10-14. (Pubitemid 351552670)
276. Machado Rocha, F. C.; Stefano, S. C.; De Cassia Haiek, R.; Rosa Oliveira, L. M.; Da Silveira, D. X. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur. J. Cancer Care (Engl) 2008, 17, 431-443.
277. Bornheim, L. M.; Lasker, J. M.; Raucy, J. L. Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol. Drug Metab. Dispos. 1992, 20, 241-246.
278. Watanabe, K.; Yamaori, S.; Funahashi, T.; Kimura, T.; Yamamoto, I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci. 2007, 80, 1415-1419. (Pubitemid 46367067)
279. Sachse-Seeboth, C.; Pfeil, J.; Sehrt, D.; Meineke, I.; Tzvetkov, M.; Bruns, E.; Poser, W.; Vormfelde, S. V.; Brockmoller, J. Interindividual variation in the pharmacokinetics of 89-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin. Pharmacol. Ther. 2009, 85, 273-276.
280. Wargo, K. A.; Banta, W. M. A comprehensive review of the loop diuretics: should furosemide be first line? Ann. Pharmacother. 2009, 43, 1836-1847.
281. Knauf, H.; Mutschler, E. Clinical pharmacokinetics and pharmacodynamics of torasemide. Clin. Pharmacokinet. 1998, 34, 1-24. (Pubitemid 28041090)
282. Miners, J. O.; Rees, D. L.; Valente, L.; Veronese, M. E.; Birkett, D. J. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J. Pharmacol. Exp. Ther. 1995, 272, 1076-1081.
283. Vormfelde, S. V.; Engelhardt, S.; Zirk, A.; Meineke, I.; Tuchen, F.; Kirchheiner, J.; Brockmoller, J. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin. Pharmacol. Ther. 2004, 76, 557-566. (Pubitemid 39610484)
284. Vormfelde, S. V.; Schirmer, M.; Toliat, M. R.; Meineke, I.; Kirchheiner, J.; Nurnberg, P.; Brockmoller, J. Genetic variation at the CYP2C locus and its association with torsemide biotransformation. Pharmacogenomics J. 2007, 7, 200-211. (Pubitemid 46785161)
285. *3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 2008, 83, 815-817. (Pubitemid 351704920)
286. Miners, J. O.; Birkett, D. J. Cytochrome P450 2C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 1998, 45, 525-538. (Pubitemid 28270907)
287. Gibbs, J. P.; Hyland, R.; Youdim, K. Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism. Drug Metab. Dispos. 2006, 34, 1516-1522. (Pubitemid 44285393)
288. Madani, S.; Paine, M. F.; Lewis, L.; Thummel, K. E.; Shen, D. D. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm Res. 1999, 16, 1199-1205. (Pubitemid 29393607)
289. Lin, J. H.; Lu, A. Y. H. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev. 1997, 49, 403-449. (Pubitemid 28030947)
290. Hamberg, A. K.; Wadelius, M.; Lindh, J. D.; Dahl, M. L.; Padrini, R.; Deloukas, P.; Rane, A.; Jonsson, E. N. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin. Pharmacol. Ther. 2010, 87, 727-734.
291. Goto, S. Is a "pharmacogenomic algorithm" helpful for adjusting the initial dose of warfarin in patients to be treated by warfarin therapy? Circ. J. 2010, 74, 850-851.
292. Klein, T. E.; Altman, R. B.; Eriksson, N.; Gage, B. F.; Kimmel, S. E.; Lee, M. T.; Limdi, N. A.; Page, D.; Roden, D. M.; Wagner, M. J.; Caldwell, M. D.; Johnson, J. A. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 2009, 360, 753-764.
293. Holstein, A.; Plaschke, A.; Ptak, M.; Egberts, E. H.; El-Din, J.; Brockmoller, J.; Kirchheiner, J. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br. J. Clin. Pharmacol. 2005, 60, 103-106. (Pubitemid 40942788)